Hikma Pharmaceuticals/£HIK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.
- Ticker
- £HIK
- Sector
- Health
- Primary listing
- LSE
- Employees
- 9,500
- Headquarters
- London, United Kingdom
- Website
- www.hikma.com
HIK Metrics
BasicAdvanced
£3.6B
13.10
£1.31
0.66
£0.64
3.71%
Price and volume
Market cap
£3.6B
Beta
0.66
52-week high
£18.65
52-week low
£11.87
Average daily volume
460K
Dividend rate
£0.64
Financial strength
Current ratio
1.981
Quick ratio
1.018
Long term debt to equity
0.691
Total debt to equity
0.771
Dividend payout ratio (TTM)
47.55%
Interest coverage (TTM)
7.01%
Profitability
EBITDA (TTM)
656.666
Gross margin (TTM)
44.05%
Net profit margin (TTM)
11.32%
Operating margin (TTM)
19.89%
Effective tax rate (TTM)
23.29%
Revenue per employee (TTM)
£268,940
Management effectiveness
Return on assets (TTM)
7.47%
Return on equity (TTM)
15.41%
Valuation
Price to earnings (TTM)
13.099
Price to revenue (TTM)
1.472
Price to book
1.48
Price to tangible book (TTM)
2.68
Price to free cash flow (TTM)
26.357
Free cash flow yield (TTM)
3.79%
Free cash flow per share (TTM)
0.653
Dividend yield (TTM)
3.71%
Growth
Revenue change (TTM)
6.31%
Earnings per share change (TTM)
5.33%
3-year revenue growth (CAGR)
7.78%
10-year revenue growth (CAGR)
7.80%
3-year earnings per share growth (CAGR)
38.62%
10-year earnings per share growth (CAGR)
7.94%
3-year dividend per share growth (CAGR)
11.52%
10-year dividend per share growth (CAGR)
10.39%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
Analyst projections of the future price of Hikma Pharmaceuticals stock.
Bulls say / Bears say
Hikma launched US fidaxomicin tablets in October, adding a product to a market it estimates at about $360 million in annual sales. Production at its Ohio site also supports its US-made medicines offering. (Hikma)
Hikma’s epinephrine nasal spray has been accepted for regulatory review in the US, UK and Europe, with a filing also made in Canada. If approved, it could add a differentiated product across several markets, though approval is not assured. (Hikma)
Injectables remains a drag: first-half revenue was flat, core operating profit fell 8% and its core margin dropped to 27.6% from 30.0%. The US division’s revenue declined 4%. (Hikma)
The 2–4% full-year revenue-growth outlook relies on a stronger second half. Management expects MENA sales to ease after first-half stockpiling and tender timing, while higher R&D and promotional spending will weigh on performance. (Investing.com, Hikma)
Supply and regional risks remain: Hikma said a partner’s manufacturing problems caused shortages in MENA, while the escalation of conflict raised logistics and business-disruption risks. The company reported no material interruption to operations so far. (Hikma)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing HIK
AllGBPUSDEUR
Fund name | Fund size | £HIK weighting |
|---|---|---|
iShares FTSE 250£MIDD | £672M | 0.79% |
Vanguard FTSE 250£VMID | £1.5B | 0.75% |
Vanguard FTSE 250£VMIG | £569M | 0.75% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.21% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.21% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.